• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Kamen blasts CMS for iBOT reimbursement call

Kamen blasts CMS for iBOT reimbursement call

June 24, 2009 By MassDevice staff

Serial inventor Dean Kamen blasted the Centers for Medicare & Medicaid Services for reimbursement decisions he said contributed to the death of the iBOT wheelchair.

“We got it through the FDA in four years, only to have CMS take the position that it should be reimbursed the same as a regular wheelchair,” he told a packed crowd of admirers at Boston University. “That’s like saying,’If you give a kid a computer in school, it’s the same as a pencil and paper,’ so you’ll reimburse the school 79 cents.”

The problem with agencies such as CMS, he added, is that “you have 19th century people looking at 21st century technology.”

Kamen is president of DEKA Research & Development Corp. of Manchester, N.H., which invented the stair-climbing, automated iBOT more than five years ago in conjunction with Johnson & Johnson subsidiary Independence Technology LLC.

Despite its advanced technology, the iBOT was shelved earlier this spring by J&J, in part because of CMS ruling that the product was little more than a traditional power-operated wheelchair and does not “serve a medical purpose.”

The iBOT, which carried price tag in excess of $25,000, was only eligible for about $6,000 in reimbursement coverage from CMS.

Kamen, delivering a keynote address in his trademark short-sleeved denim shirt and jeans at the XSite 2009 conference hosted by high-tech blog Xconomy.com, said innovation faces “insidious” foes determined to halt progress.

“Innovation is limited by the fact that people don’t like change,” Kamen said, in a rousing speech that lasted more than an hour and ended to a standing ovation (and at least one call of “Dean for president”).

The strong could signal another battle with the agency Kamen might face over his DEKA arm, a robotic prosthetic he developed for the Defense Advanced Research Projects Agency that’s far more advanced than any prosthetic on the market. If the arm ever makes it to market, it’s likely to face a similar pricing and reimbursement challenge.

Kamen, who started his career inventing products including insulin pumps and portable dialysis machines that were bought by companies like Medtronic and Baxter, said the medical industry should start looking to industries such as aerospace to solve design problems in innovative products.

“If you continue looking inside your own industry, you’re only destined to make incremental improvements,” he noted. “If you go outside your industry, they might fail, but they also might solve some problems.”

Kaman called on the innovators in attendance to get out into the community and work with young people. He devoted a considerable portion of the speech to his FIRST (For Inspiration and Recognition of Science and Technology) robotic design competition for elementary, middle and high school students.

“I spent two hours in traffic coming here, so you’re going to hear about FIRST,” he joked, drawing big laughs when he said that he would have flown his helicopter down from Manchester but “people in this city are afraid of technology.”

* Kamen on the Segway: “I spent 30 years making medical equipment and know I’m only known as ‘the Segway guy.'”

* Kamen on the flack he took for an infamous picture of former President George W. Bush falling off a Segway: “I said, ‘It works so much better if you turn it on before you jump on it.'”

* Kamen on innovation: “I’m an innovator so I’m nuts … until I’m right and then the answer was obvious.”

Filed Under: Uncategorized

More recent news

  • Massachusetts Life Sciences Center offers grants to lower medtech commercial risk
  • The 10 largest medical device companies
  • CSL to drop Terumo for Haemonetics in US plasma collection supply deal
  • How 5 medtech CEOs design for access
  • Butterfly Network to chase ultrasound brain-computer interfaces with newcomer Bridge Neurotech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy